Reconstituted HDL: Drug delivery platform for overcoming biological barriers to cancer therapy

Sangram Raut, Linda Mooberry, Nirupama Sabnis, Ashwini Garud, Akpedje Serena Dossou, Andras Lacko

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, “nature's drug delivery system,” while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.

Original languageEnglish
Article number1154
JournalFrontiers in Pharmacology
Issue numberOCT
StatePublished - 15 Oct 2018


  • Biological barriers
  • Cancer therapy and imaging
  • Cholesterol
  • HDL
  • RHDL
  • SR-B1 receptor
  • Tumor targeting


Dive into the research topics of 'Reconstituted HDL: Drug delivery platform for overcoming biological barriers to cancer therapy'. Together they form a unique fingerprint.

Cite this